Johnson & Johnson ($JNJ) received 58 mentions from 12 distinct FinTwit voices over the past 12 months, with the first mention appearing on August 27, 2025, and the most recent on July 13, 2026. @jacobplieth dominated discussion with 40 mentions, followed by @adamfeuerstein with 12 mentions. The biotech category represented the most active voice segment discussing the stock. Discussion centered on $JNJ's earnings performance, with voices noting Innovative Medicine products including Darzalex and Carvykti driving approximately 5.5% year-over-year revenue growth and four consecutive earnings beats.